HIV therapy Rezolsta approved by EC

25 November 2014
janssen-logo-big

Belgium-based Janssen-Cilag International NV, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), has announced that the European Commission has approved the use of Rezolsta (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of HIV-1 infection in adults aged 18 years or older.

The decision follows a Positive Opinion recommending the use of Rezolsta from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in September. At that time, the CHMP also announced two label indication extensions for darunavir, a protease inhibitor marketed as Prezista by Janssen, which have also been approved by the EC.

Rezolsta is a new once-daily, fixed-dose combination tablet containing darunavir and the pharmacokinetic enhancing or “boosting” agent Tybost (cobicistat) by US biotech major Gilead Sciences (Nasdaq: GILD). The darunavir and cobicistat fixed-dose combination was approved in Canada in June 2014 under the name Prezcobix, and is currently undergoing regulatory review by the US Food and Drug Administration. Janssen said it will continue to make darunavir available as a single agent in tablets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical